Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyFrancesco Passamonti, Celestino Ferrandina, Nicola Giuliani et al.|The Lancet Haematology|2020Cited by 553
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow TransplantationMohamad Mohty, Rafael F. Duarte, Kai Hübel et al.|Bone Marrow Transplantation|2014Cited by 192
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilizationKai Hübel, Rafael F. Duarte, M M Fresen et al.|Bone Marrow Transplantation|2011Cited by 65
Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or LenalidomideFlorent Malard, Rafael F. Duarte, Nicolaus Kröger et al.|Biology of Blood and Marrow Transplantation|2011Cited by 44
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World StudyFrancesca Palandri, Massimo Breccia, Elena Maria Elli et al.|Cancer|2024Cited by 10